Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod in Early-Stage Oral Squamous Cell Carcinoma
NCT04883645Phase 1Completed
- Sponsor
- Medical University of South Carolina
- Start
- Apr 2022
- Primary completion
- Jun 2023
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of imiquimod in oral squamous cell carcinoma (OSCC), sponsored by Medical University of South Carolina. Primary endpoint: Number of Participants With 50% Reduction in Tumor Cell Count and Major Pathologic Response at 28 days. Started Apr 2022; status: completed.
02
Drugs
imiquimod
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT04883645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04883645.